Japan’s Laws Supporting Accelerated Pathways for Cell …

By Dr. Matthew Watson

In late 2014, Japan passed two new laws that revolutionizedthe commercialization ofcell therapies within the country by providing an accelerated pathway for product approvals. While there has been much discussion about these laws, few people have a clear understanding of the implications of these regulations on a global scale.

Below, we summarize the laws, identify their importance, and most importantly, speak to howJapan has become a gateway country for regenerative medicines.

New regulations accelerating the approval of regenerative therapeutics in Japan took effect November 25, 2014. The significance of these regulations is that they allow companies to receive conditional marketing approval and commercialize regenerative medicine products while clinical trials continue through the later stages.

The accelerated commercialization of cell therapies is part of the economic revitalization plan initiated by Prime Minister Shinz Abe. Under Shinz Abe, Japan has been pursuing regenerative medicine and cellular therapy as key strategies to the Japans economic growth. Japans Education Ministry also indicated that it is planning to spend 110 billion yen ($1.13 billion) on iPS cellresearch during the next 10 years, and the Japanese parliament has been discussing bills that would speed the approval process and ensure the safety of such treatments.[1]

In late 2014, Japan exercised the following acts:

The aim of the first act was to accelerate the clinical application and commercialization of innovative regenerative medicine therapies. It covers clinical research and medical practice using processed cells and specifies the procedure required for clearance to administer cell procedures to humans. These guidelines are very important to the use the cells within clinical stages.

The PMD Acts definition of regenerative medicine includes tissue-engineered products, cell therapy products, and gene therapy products.

The intent of the laws is to accelerate the commercialization of cell therapeutics within Japan by allowing companies to benefit from conditional marketing authorization.

Therefore, cell therapies that show safety and probable efficacy during Phase I and Phase II trials can get conditional approval for up to seven years, during which time:

1) Larger-scale, later-stage clinical trials are performed2) Revenue from the cell therapy is pursued within the Japanese market

During the seven-year conditional approval period, companies must continue to submit clinical trial data to Japans Pharmaceuticals and Medical Devices Agency (PMDA), and subsequentlyapply for final marketing approval or withdraw the product within seven years.

This safety data can then be used by non-Japanese participants, which is a massive benefit to foreign companies, such as those located in the United States. The regulatory environment in Japan provides companies with the unique opportunity to fast track a clinical trial and seek approval of a new cell therapy product within the Japanese market.

As Kaz Hirao, CEO of Cellular Dynamics International (CDI), shared with BioInformant:This has made Japan a gate country for developing innovative cell therapies with the potential to address major unmet medical needs. It has has provided a strategic opportunity to American companies, because they can benefit from fast track applications through doing clinical testing within Japan and subsequently developing its cell therapy across the rest of the world. Numerous American and Australian companies are pursuing this strategy, as well as other companies from other countries worldwide.[2]

Footnotes[1] Dvorak, K. (2014).Japan Makes Advance on Stem-Cell Therapy[Online]. Available at: http://online.wsj.com/news/articles/SB10001424127887323689204578571363010820642. Web. 8 Apr. 2015.[2]Interview with Kaz Hirao, CEO of Cellular Dynamics International (CDI), a FUJIFILM Company. Conducted by BioInformants President/CEO, Cade Hildreth [January 29, 2017]. Available at: https://bioinformant.wpengine.com/cellular-dynamics-cdi-kaz-hirao/.

Japans Laws Supporting Accelerated Pathways for Cell Therapies

Originally posted here:
Japan's Laws Supporting Accelerated Pathways for Cell ...

Related Post

categoriaIPS Cell Therapy commentoComments Off on Japan’s Laws Supporting Accelerated Pathways for Cell … | dataMarch 12th, 2019


This author published 3424 posts in this site.


FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.

Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research